BMY - Bristol-Myers Squibb Company
47.16 -0.27 (-0.57%)
After hours: 7:23PM EDT
| Previous Close | 46.31 |
| Open | 46.55 |
| Bid | 47.42 x 3100 |
| Ask | 47.38 x 1400 |
| Day's Range | 46.48 - 47.46 |
| 52 Week Range | 44.30 - 63.69 |
| Volume | 10,942,641 |
| Avg. Volume | 18,632,154 |
| Market Cap | 77.582B |
| Beta (3Y Monthly) | 0.85 |
| PE Ratio (TTM) | 15.11 |
| EPS (TTM) | 3.14 |
| Earnings Date | Jul 24, 2019 - Jul 29, 2019 |
| Forward Dividend & Yield | 1.64 (3.53%) |
| Ex-Dividend Date | 2019-04-04 |
| 1y Target Est | 57.30 |
- Yahoo Finance Video•12 days ago
Why this former health care CEO thinks this Uber board member is crucial to its success
Yahoo Finance's Alexis Christoforous and Brian Sozzi talk to former Aetna CEO and friend of Uber board member Ursula Burns about the current state of healthcare, the anticipation ahead of the Uber IPO and overall stocks that are gaining attention in the market.
- Financial Times•13 hours ago
Merck agrees $1bn deal to buy biopharmaceutical company Peloton
US pharmaceutical company Merck has agreed a $1.05bn cash deal to buy Peloton Therapeutics, gaining access to the biopharmaceutical company’s renal cancer drug treatment that is in development. Peloton had been planning an initial public offering in New York, and its shareholders will be eligible to receive an additional $1.15bn, dependent on future regulatory and sales milestones. The company is in the late-stage development of a treatment for renal cell carcinoma, which Merck said has shown “intriguing activity” in the treatment of the kidney cancer.
- GuruFocus.com•yesterday
4 New Stock Picks From Seth Klarman
While value investors continue to read through Seth Klarman (Trades, Portfolio)'s most recent partnership letter, others are tracking his latest filings to see what the guru has deemed worthy of buying. Warning! GuruFocus has detected 3 Warning Sign with CDAY.
- Benzinga•yesterday
Argus Questions Logic Behind Bristol-Myers' Proposed Celgene Buy, Steps To Sidelines
Bristol-Myers Squibb's growth prospects following the planned acquisition of Celgene are a cause of concern, Toung said in a Friday downgrade note. Revlimid is Celgene's best-selling multiple myeloma drug and showed 15-percent year-over-year growth to $2.58 billion in the first quarter of 2019. It fetched roughly 64 percent of the company's revenues.
- MarketWatch•yesterday
Drugmakers’ lobbying spending at 10-year high as Washington targets soaring prices
The spending by the industry’s main trade group and seven key drugmakers has climbed to a level not seen in a decade.
- Barrons.com•yesterday
Bristol-Myers Stock Is Falling Because the Celgene Merger May Not Make Sense
A stormy honeymoon could be in the offing following the biggest pharmaceutical acquisition in history, according to one analyst.
- Zacks•4 days ago
Roche Gets FDA Nod for Venclexta Plus Gazyva to Treat CLL
Roche (RHHBY) gains an FDA nod for the sNDA of its leukemia drug, Venclexta, in combination with Gazyva for the treatment of previously untreated chronic lymphocytic leukemia.
- Zacks•4 days ago
Celgene Gets EC Nod for Label Expansion of Revlimid, Imnovid
Celgene (CELG) obtains approval for the label expansion of oncology drugs Revlimid and Imnovid in Europe.
- Business Wire•5 days ago
Bristol-Myers Squibb to Present New Data on 20 Types of Cancer from Across its Oncology Portfolio at ASCO and EHA 2019
New data on Opdivo plus Yervoy in patients with advanced hepatocellular carcinoma and in melanoma patients with symptomatic brain metastases
- TheStreet.com•5 days ago
Bristol-Myers Squibb: A Long Idea for Aggressive Traders Only
In the Lightning Round of Wednesday's Mad Money program, Jim Cramer favored Bristol-Myers Squibb Co. which has been in a downtrend from August," Cramer told viewers. In the daily bar chart of BMY, below, we can identify three trends in the past twelve months.
- GlobeNewswire•6 days ago
Biocartis Group NV: Idylla(TM) MSI Performance Study Selected for Publication at ASCO Conference
PRESS RELEASE : 16 May 2019, 07:00 CEST Idylla(TM) MSI Performance Study Selected for Publication at ASCO Conference Mechelen, Belgium, 16 May 2019 - Biocartis Group NV (the `Company` or `Biocartis`), ...
- Zacks•6 days ago
Pfizer's Bavencio+Inlyta Combo Gets FDA Nod for Kidney Cancer
Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets approval in the United States.
- CNBC•7 days ago
Lawsuit accuses Gilead of propping up cost of lifesaving HIV treatments by blocking generic competition
Pharmaceutical giant Gilead Sciences engaged in a "long-running scheme" to block generic competition of its combination drug "cocktails" to treat HIV. The complaint, filed in the U.S. District Court in San Francisco, names drugmakers Bristol-Myers Squibb and Johnson & Johnson subsidiary Janssen Pharmaceuticals as co-defendants. The plaintiffs in the suit claim that Gilead's actions caused the cost of the life-saving treatment to rise.
- GuruFocus.com•7 days ago
These Sleepy Stocks Have Done Nothing, But May Wake Up
This is a club for stocks that have hardly budged from where they were a month ago, and a year ago. Such stocks are often neglected by investors and sometimes by analysts too. Warning! GuruFocus has detected 3 Warning Signs with FLR.
- Zacks•7 days ago
Zacks.com featured highlights include: BlackRock, Northrop, Progressive, Interpublic Group and Bristol-Myers
Zacks.com featured highlights include: BlackRock, Northrop, Progressive, Interpublic Group and Bristol-Myers
- Business Wire•8 days ago
Award-Winning Actor and Producer Sterling K. Brown Joins Bristol-Myers Squibb in Effort to Share Stories of What It’s Like to Live with Cancer Today
Two-time Emmy Award winner Sterling K. Brown (This Is Us, Black Panther) is partnering with Bristol-Myers Squibb on a series designed to illuminate the triumphs and challenges of life after a cancer diagnosis. Survivorship Today: What It’s Like to Live with Cancer explores the stories of people who have experienced lasting physical, emotional and social effects from cancer to build greater understanding of, and draw attention to, survivorship-related issues. Today, more people who have been diagnosed with cancer are able to live with the disease than ever before.
- Business Wire•8 days ago
Bristol-Myers Squibb to Take Part in the UBS Global Healthcare Conference
Bristol-Myers Squibb Company will take part in a fireside chat at the UBS Global Healthcare Conference on Tuesday, May 21, 2019, in New York. Giovanni Caforio, M.D., chairman and chief executive officer will answer questions at 2:30 p.m.
- GuruFocus.com•8 days ago
Why Bristol-Myers Squibb's $19 Billion Debt Issuance to Buy Celgene Makes Sense
Bristol-Myers Squibb's (BMY) move to raise close to $20 billion in debt to acquire Celgene (CELG) looks dangerous, but years from now it may be considered a savvy move. True, the huge aggregate number of $58 billion in combined debt between the two companies certainly doesn't look all that flattering, especially in the context of threats by all three credit rating agencies - Moody's, Fitch and S&P Global Ratings - to downgrade the company's credit rating. The ratings agencies correctly cite total debt at 4x earnings, and that makes the corporate bond markets justifiably jittery.
- Zacks•8 days ago
Buy These 5 Stocks With Impressive Sales Growth Right Away
Sales growth is a key measure for any company, as it is important for growth projections and strategic decision making.
- Zacks•8 days ago
Bristol-Myers (BMY) is an Incredible Growth Stock: 3 Reasons Why
Bristol-Myers (BMY) could produce exceptional returns because of its solid growth attributes.
- Zacks•11 days ago
AVEO Pharmaceuticals (AVEO) Q1 Earnings & Revenues Miss Mark
AVEO Pharmaceuticals (AVEO) discourages investors in Q1 with wider-than-expected loss as well as a revenue miss. Also, Fotivda NDA gets delayed as the FDA was dissatisfied with the OS data.
- Zacks•11 days ago
Endo (ENDP) Q1 Earnings & Revenues Beat Estimates
Endo's (ENDP) earnings and revenues top expectations in the first quarter of 2019.
- Simply Wall St.•12 days ago
Can Bristol-Myers Squibb Company's (NYSE:BMY) ROE Continue To Surpass The Industry Average?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
- Zacks•12 days ago
Nektar (NKTR) Q1 Earnings & Revenues Beat, Decline Y/Y
Nektar's (NKTR) earnings and sales beat estimates in the first quarter. The company is progressing well with its pipeline candidates.
